-
1.发明授权
公开(公告)号：EP0689675B1
公开(公告)日：2001-11-14
申请号：EP94911584.4
申请日：1994-03-14
CPC分类号： C12Q1/28 , A61B10/0038 , G01N33/725 , Y10T436/25125
摘要： The presence of fecal occult blood in a stool sample is detected by mixing a liquid stool sample with an acidic liquid, such as a phosphate/citrate buffer, to precipitate hematin from the solution. The precipitated hematin is separated and the presence of absence of hemoglobin is determined by exposing the solution to a peroxidase diagnostic assay. A positive response indicates the presence of blood originating in the lower gastrointestinal tract, a leading indicator of lower GI cancer.
-
2.发明公开APPARATUS FOR ANALYZING SUBSTANTIALLY UNDILUTED SAMPLES OF BIOLOGIC FLUIDS 有权设备用于分析生物液体的本质UNRESOLVED样品
公开(公告)号：EP1070251A1
公开(公告)日：2001-01-24
申请号：EP99909728.0
申请日：1999-03-02
IPC分类号： G01N33/48
CPC分类号： G01N33/5002 , G01N15/05 , G01N15/1463 , G01N2015/0076 , G01N2015/008 , G01N2015/0084 , G01N2015/055 , G01N2015/145 , G01N2015/1465 , G01N2015/1486 , G01N2015/1497
摘要： An apparatus for analyzing a sample of biologic fluid quiescently residing within a chamber (20) is provided. The apparatus includes a field illuminator (40), a positioner (86), a mechanism for determining the volume of a sample field, and an image dissector (42). The field illuminator (40) is operable to illuminate a sample field of known, or ascertainable, area. The positioner (86) is operable to selectively change the position of one of the chamber (20) or the field illuminator (40) relative to the other, thereby permitting selective illumination of all regions of the sample. The mechanism for determining the volume of a sample field can determine the volume of a sample field illuminated by a light source. The image dissector (42) is operable to convert an image of light passing through or emanating from the sample field into an electronic data format.
-
公开(公告)号：EP0693901A1
公开(公告)日：1996-01-31
申请号：EP94910933.0
申请日：1994-03-14
CPC分类号： A61B10/0038
摘要： The specification discloses a method for enhancing the reliability of screening tests used for detecting the presence or absence of chemical markers associated with gastrointestinal cancer. The method comprises the steps of providing a laxative purge for administration to a patient, collecting a watery fecal sample and then applying the watery fecal sample to a test medium having an indicator to indicate the presence of chemical markers associated with gastrointestinal cancer, if there. Two alternative methods are suggested for obtaining a watery fecal sample. In a first embodiment, the purge is administered to the patient following a recent bowel movement and the first watery post-purge bowel movement is collected. In a second embodiment, the purge is administered to the patient, the first post-purge bowel movement is discarded and the second watery post-purge bowel movement is collected.
-
4.发明公开Determination of lymphocyte reactivity to specific antigens in blood 失效Nachweis derReaktivitätvon Lymphozytengegenüberspezifischen Antigenen im Blut。
公开(公告)号：EP0393334A2
公开(公告)日：1990-10-24
申请号：EP90103895.0
申请日：1990-02-28
IPC分类号： G01N33/569
CPC分类号： G01N33/5091 , G01N33/56972 , Y02A50/57 , Y10S435/975 , Y10T436/25375
摘要： A patient's blood sample is incubated with an antigen and tested for lymphocyte response, ie. an activation of lymphocytes and/or a conversion of lymphocytes to lymphoblasts, which indicates prior exposure of the patient to the antigen. A positive response indicates the presence of prior exposure to prior diseases or clinical conditions such as parasitic diseases, tuberculosis, salmonellosis, gonorrhea, fungal infections, rickettsial infections, Lyme disease or allergens. Whole blood from the patient is incubated with the antigen of the disease or condition for which the patient is being tested. After a suitable time, a fluorescent dye or colorant which has an affinity for a discriminant characteristic of the activated lymphocytes or lymphoblasts, such as: intracellular calcium; surface activation antigens such as transferrin receptor; HLA-Dr; Leu-23; and the like. The incubated blood is then drawn into a transparent tube containing a float which concentrates the buffy coat constituent layers upon centrifugation of the blood sample. The concentrated lymphocyte layer is then examined for fluorescence or coloration which is indicative of the presence of the activated lymphocytes or lymphoblasts, and their concentration. The fluorescence or coloration can be qualified and/or quantified by a reader instrument.
摘要翻译： 将患者的血液样品与抗原孵育并测试淋巴细胞反应，即。 淋巴细胞的激活和/或淋巴细胞转化成淋巴母细胞，其指示患者事先暴露于抗原。 阳性反应表明先前接触先前疾病或临床病症如寄生虫病，结核病，沙门氏菌病，淋病，真菌感染，立克次体感染，莱姆病或过敏原。 将来自患者的全血与患者正在测试的疾病或病症的抗原一起温育。 在合适的时间之后，对活化的淋巴细胞或淋巴母细胞的鉴别特征具有亲和性的荧光染料或着色剂，例如：细胞内钙; 表面活化抗原如转铁蛋白受体; HLA-DR; LEU-23; 等等。 然后将孵育的血液吸入含有浮子的透明管中，该浮子在血液样品离心时浓缩血沉棕黄层组成层。 然后检查浓缩的淋巴细胞层的荧光或着色，其指示活化的淋巴细胞或淋巴母细胞的存在及其浓度。 荧光或着色可由阅读器仪器进行鉴定和/或定量。
-
5.发明公开Determination of white blood cell differential and reticulocyte counts 有权BESTIMMUNG DES LEUKOZYTEN-DIFFERENTIALS UND RETICULOZYTEN-ZÄHLUNG
公开(公告)号：EP2267443A1
公开(公告)日：2010-12-29
申请号：EP10184474.4
申请日：1999-02-22
申请人： Wardlaw Partners LP , Becton, Dickinson & Company , Wardlaw, Stephen Clark , Levine, Robert Aaron
CPC分类号： G01N15/1475 , G01N33/5094 , G01N2015/0076 , G01N2015/0092 , G01N2015/1472 , G01N2015/1497 , Y10T436/10 , Y10T436/101666
摘要： Target nucleated cells, and target cells containing remnant ribosomal material, which are present in a quiescent anticoagulated whole blood sample are optically detected, enumerated, and analyzed in a sample chamber (14) that has a varying through plane thickness due to convergent opposing sample chamber walls. At least one of the convergent walls (8) of the chamber is transparent so that the blood sample can be observed. The chamber's varying thickness produces a first lesser thickness region (A) in the chamber wherein individual red cells (32) and quiescent monolayers (31) of red cells in the sample will reside after the sample is introduced into and fills the chamber. Larger formed constituents such as white blood cells (34) and nucleated red blood cells present in the sample will reside in greater thickness regions (B) of the chamber, and non-nucleated red cells which reside in such greater thickness regions will agglomerate to form rouleaux (33). By admixing fluorescent dyes with the blood sample, target cells in the sample can be enumerated and differentiated by means of a scanning instrument (54) which is able to measure different wave length color signals emitted from the target cells in the sample, and differentiate the target cells one from another by reason of the nature of the emitted color signals.
摘要翻译： 存在于静止抗凝全血样品中的目标有核细胞和含有残留核糖体材料的靶细胞在由于收敛的相对样品室而具有不同的平面厚度的样品室（14）中被光学检测，列举和分析 墙壁。 室的收敛壁（8）中的至少一个是透明的，使得可以观察血液样本。 室的不同厚度在腔室中产生第一较小厚度的区域（A），其中样品中的红细胞中的各个红细胞（32）和静止单层（31）将在样品被引入并填充室之后驻留。 样品中存在的白细胞（34）和成核红细胞等较大的成分将存在于室的较大厚度区域（B）中，并且驻留在这样较厚的区域中的未成核红细胞将聚集形成 rouleaux（33）。 通过将荧光染料与血液样品混合，样品中的靶细胞可以通过能够测量从样品中的靶细胞发射的不同波长颜色信号的扫描仪器（54）进行计数和分化，并区分 由于发射的颜色信号的性质，目标细胞彼此之间。
-
6.发明授权
公开(公告)号：EP0877094B1
公开(公告)日：2006-09-27
申请号：EP98107881.9
申请日：1998-04-29
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6851 , C12Q1/6834 , C12Q1/6846
-
7.发明公开Process for enhancing the aggregation and/or agglutination of erythrocytes prior to centrifugation 失效一种用于向离心之前提高红血细胞的聚集和/或凝集过程
公开(公告)号：EP0844482A3
公开(公告)日：1999-12-29
申请号：EP97120380.7
申请日：1997-11-20
摘要： A sample of anticoagulated mammalian whole blood is admixed with a combination of reagents that will reduce the natural repulsive forces that mammalian erythrocytes have for each other. The treated blood sample is then centrifuged in a tube containing a buffy coat expanding insert thereby physically expanding the axial extent of the blood sample s buffy coat components in the tube. By reducing the tendency of the erythrocytes to repel each other, a clearer demarcation between the erythrocytes and the buffy coat can be achieved. The effect of agglutinating reagents which may have been added to the blood sample will also be enhanced. The aforesaid procedure and reagents make it possible for the first time to accurately analyze a centrifuged sample of anticoagulated bovine whole blood and obtain hematocrit and differential white cell counts therefrom. Additionally, human blood samples which otherwise exhibit a streaming tendency can also be accurately analyzed by the addition of a combination of the appropriate erythrocyte repulsion-reducing reagents along with agglutinating reagents.
-
8.发明公开
公开(公告)号：EP0877094A2
公开(公告)日：1998-11-11
申请号：EP98107881.9
申请日：1998-04-29
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6851 , C12Q1/6834 , C12Q1/6846
摘要： A target analyte which may be found in a substance, such as a biological or environmental substance, is assayed by inoculating a media with a sample of the substance. The target analyte is a unique nucleotide sequence of the RNA or DNA of a suspect organism, or any nucleotide target, or a combination of nucleotide sequences thereof, which organism may be found in the substance. The media contains selected target analyte amplifiers which will result in the amplification of any target analytes which are present in the substance. The media may also contain one or more labeled analyte-specific materials (LASMs) which can migrate through the media. The nature of the media is such that it will support target analyte-copying but will not allow the target analyte to migrate extensively within the media. After the substance to be assayed is added to the media and any target analytes are amplified, the LASMs will migrate by diffusion to resultant target analyte units or colonies in the media, thereby creating intensely labeled localized areas in the media which can be visually or mechanically detected. Each of the intensely labeled areas in the media will be surrounded by low intensity label halos. The number of high intensity labeled sites in the media will be proportional to the concentration of target analytes in the substance.
摘要翻译： 试验作为生物或环境物质，其可以在物质中找到的靶分析物，是通过接种媒体与该物质的样品进行测定。 目标分析物是RNA或可疑有机体的DNA，或者任何核苷酸靶，或其核苷酸序列的组合，其中生物可在物质中找到的唯一核苷酸序列。 媒体包含所选的目标分析物放大器whichwill导致任何靶分析物是存在于该物质的扩增。 因此，该介质可以包含一种或多种标记的分析物特异性物质（LASMs），其可以通过媒体迁移。 媒体的本质检查做到了willsupport目标分析物，抄袭，但不会允许目标分析物向媒体中得到了广泛迁移。 待测定的物质被添加到所述介质和任何目标分析物被放大后，LASMs将通过扩散迁移到合力的靶分析物单位或菌落在媒体上，从而产生强烈的媒体标记的局部区域从而可以在视觉上或机械 检测。 在媒体的强烈标记的各项将通过低强度标签的光环所包围。 在媒体高强度标记的位点的数目将正比于目标分析物的物质中的浓度。
-
公开(公告)号：EP0493838B1
公开(公告)日：1997-05-28
申请号：EP91122385.7
申请日：1991-12-30
CPC分类号： G01N33/491 , B01L3/50215 , Y10T436/25375 , Y10T436/2575
-
10.发明公开Determination of an individual's inflammation index from whole blood fibrinogen and hematocrit or hemoglobin measurements 失效包括生物个体的炎症指标，基于Vollblutfibrinogens的测量和血细胞比容或血红蛋白含量的测定
公开(公告)号：EP0715170A2
公开(公告)日：1996-06-05
申请号：EP95118964.6
申请日：1995-12-01
CPC分类号： C12Q1/56 , G01N33/721 , G01N33/86 , G01N2333/75 , G01N2333/805
摘要： Useful information about a subject's level of systemic inflammation is obtained by quantitatively measuring the amount of fibrinogen and the hematocrit and or hemoglobin in the subject's whole blood. The fibrinogen measurement, when combined with an hematocrit or hemoglobin measurement, provides a systemic Inflammation Index value for the donor. The method is not affected by blood variables which are not related to the presence of inflammation, which blood variables are known to invalidate an erythrocyte sedimentation rate, which is the most frequently used blood test for detecting systemic inflammation in humans.
摘要翻译： 哺乳动物供体全身性炎症的被度确定性从血液样品从供体被吸入到一个透明管（2）contg抗凝的全血供体的样品开采。 细长浮体（4）。 将样品在管离心。 在管中的血样中纤维蛋白原/纤维蛋白的量进行测量。 对于在管中的血液样品血细胞比容血红蛋白或值确定性开采。 I，表示全身性炎症的程度的，通过求解式（i）计算出的数I = A（F）+ B（H）+ C其中，f是样品中测得的纤维蛋白原/纤维蛋白水平; h是样品中的确定性开采血细胞比容血红蛋白或值; 并且a，b和c是经验常数。 的余数值与度相关。 哺乳动物的供体全身性炎症。
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.015 秒)
